Global Schistosomiasis Diseases Market, By Type (Schistosoma Mansoni, Schistosoma Japonicum, Others), Drugs (Praziquantel, Metrifonate, Oxamniquine, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Schistosomiasis Diseases Market Dynamics Analysis and Size
The global schistosomiasis diseases market is expected to witness significant growth during the forecast period. Evaluations show that at least 236.6 million people are required to have preventive treatment in 2019. Preventive treatment, helps in decreasing the disease occurence and prevent morbidity. Preventive chemotherapy is generally preferred for schistosomiasis, mostly in 51 endemic countries with moderate-to-high transmission
Data Bridge Market Research analyses a growth rate in the global schistosomiasis diseases market in the forecast period 2022-2029. The expected CAGR of global schistosomiasis diseases market is tend to be around 4% in the mentioned forecast period. The market was valued at USD 70 million in 2021, and it would grow upto USD 95.80 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Schistosomiasis Diseases Market Dynamics Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Million, Volumes in Units, Pricing in USD
Type (Schistosoma Mansoni, Schistosoma Japonicum, Others), Drugs (Praziquantel, Metrifonate, Oxamniquine, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Abbvie, Inc (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), Bausch Health Companies Inc. (Canada), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Seagen, Inc (U.S.), ONO Pharmaceutical Co., Ltd. (Japan)
Schistosomiasis is also known as bilharzia, a tropical disease caused by a group of parasitic worms called blood flukes belonging to the genus Schistosoma. The disease is transmitted through the consumption of freshwater infected from the larva of parasitic worms. This parasite penetrates into the human skin to reach blood stream and travel to the liver, intestine and other organs. The characteristics sign and symptoms of the abdominal pain, chills and fatigue.
Global Schistosomiasis Diseases Market Dynamics
- Increasing Cases of Schistosomiasis
Around 700 million people are at higher risk of infection in 76 countries where the disease is considered to be endemic, because their agricultural work, domestic chores, and recreational activities rendering them to infested water. Approximately 200,000 deaths worldwide are accredited to schistosomiasis annually. WHO estimates that in 2019, around 236.6 million people required preventive treatment for schistosomiasis, out of which above 105.4 million people were recorded to have been treated in 2019. This boosts the market growth.
- Rising Demand for Oral Drugs
Oral drugs is definitely pushing the market growth to a great extent. The segment is projected to increase the global market as many of the products are available in capsule and tablet form and it is a very suitable route of administration.
- Rising Development of Novel Vaccines
Several novel vaccines are developed that create more market growth opportunities. For instance, on 1st June 2021, The International Vaccine Institute (IVI) received a grant from the Bill & Melinda Gates Foundation to develop the phase Ib/IIa protocol for the schistosomiasis vaccine. Some vaccines are still under development, while some vaccines in patent applications have also been filed in China, India, and Brazil. This development is projected to augment the growth of the schistosomiasis diseases market.
- Rising Healthcare Awareness
Health awareness amongst the population are rising which results in the prediction of drugs boost the market growth. The innovative launches in medications for the treatment of ovarian cancer are expected to prompt the market simultaneously. Different researchers are investing in launching the drugs that benefit the market. This creates more opportunities in the market.
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the schistosomiasis diseases market over a forecast period.
- High Cost
The huge expenditure of treatment methods hamper the market growth. Many a times, due to lack of appropriate payment plans and special considerations by the organizations, the patients fail to adapt these high-end treatment options which in return hampers their health. Thus, this is an important restrain that needs to be taken care of.
This schistosomiasis diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the schistosomiasis diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Schistosomiasis Diseases Market Scope
The schistosomiasis diseases market is segmented on the basis of type, drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Schistosoma Mansoni
- Schistosoma Japonicum
Route of Administration
- Speciality Centres
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Schistosomiasis Diseases Market Regional Analysis/Insights
The schistosomiasis diseases market is analyzed and market size insights and trends are provided by type, drugs, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the schistosomiasis diseases market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the high demand for disease-specific treatment, increased patient awareness level as well as high prevalence of this diseases.
Asia-Pacific dominates the market due to the number of generic manufacturers in this region and increasing disposable income.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Schistosomiasis Diseases Market Share Analysis
The schistosomiasis diseases market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to schistosomiasis diseases market.
Key players operating in the schistosomiasis diseases market include:
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- AbbVie Inc. (U.S.)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Merck KGaA (Germany)
- LEO Pharma A/S (Denmark)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Amneal Pharmaceuticals LLC. (U.S.)